- Chiesi Group has been named on Carbon Disclosure Project’s Climate Change A List for its commitment to climate action and transparency.
- The Group has also received from Cerved Rating Agency the AA ESG rating with an overall score of 75.1 out of 100.
- According to the independent rating agency, Chiesi is ranking in the top quintile of best-performing companies in the ’Healthcare Products’ sector, scores high in terms of emission reduction, gender balance, and training ratio.
Parma (Italy) January 17th, 2023 – Chiesi, the international research-focused biopharmaceutical group, has been named on Carbon Disclosure Project’s Climate Change A List for its commitment to climate action and transparency, placing among the 283 companies (out of approximately 15,000 that submitted data for evaluation) in the world that have achieved this recognition. This is higher than Europe regional average of B and higher than the Biotech & Pharma sector average of B.
CDP is the world’s most recognised body for assessing the progress of greenhouse gas emissions reductions, strategies, and concrete actions to combat climate change and it holds the largest environmental database in the world. A turning point on the path to this year´s success is the developments in the company´s emissions reduction strategy, with results to 2021 confirming alignment with targets.
In addition, the Group has obtained an AA rating for its outstanding capacity to manage environmental, social, and governance (ESG) risks and opportunities from the independent Italian player Cerved Rating Agency. The second-highest attainable rating places Chiesi in the top quintile of the best-performing companies in the ‘Health Products’ sector, according to the recently published final assessment.
As a result of the score recorded and the progress shown, Chiesi’s ESG rating rose to AA compared with the A rating in 2021. 75.1 points out of 100 reflects company´s overall performance improvement over the past year. In particular, Cerved Rating Agency highlights excellent results in a number of important areas, including emission reduction, gender balance, and training ratio among employees.
The agency also commends the continued Chiesi’s work on the new carbon minimum inhaler and energy efficiency, pursuing targets to increase the share of renewable energy. On the environmental side, it is highlighted that significant progress has been made to reduce waste generation and increase recovery rate. Performance concerning the management of social variables remained high, the Cerved Rating Agency added. The number of permanent contracts has increased compared to 2020, staff training ratios is high, and the company features a positive gender balance.
According to Cerved Rating Agency, a well-structured governance on sustainability exists in Chiesi Group and the assessment of corporate governance appears positive. A coordinated ESG management structure is reporting directly to the board in the Shared Value and Sustainability function. Additionally, an inter-management Impact Committee for monitoring ESG objectives and their implementation is in place.
“We are excited and proud about the newest rating. And we are aware of the fact that one can only achieve such a result if all employees work together,” says Maria Paola Chiesi, Shared Value & Sustainability Head of Chiesi Group. “But our work isn´t done yet. ESG reports are much more than just highlighting a company’s sustainability progress. They not only accentuate strengths, but also uncover weaknesses and room for further improvement. We know that we need to involve suppliers and partners to a greater extent and broaden virtuous sustainability processes throughout the value chain. Therefore, a positive ESG rating is both a confirmation and an incentive for us. It is never an end point, but always a starting point to identify new opportunities and initiate improvements. Chiesi will continue to strive for using business as a force for good.”
About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. Since 2019 Chiesi is certified B Corp, meaning that its sustainability efforts are measured and assessed by the most ambitious global standards. The company aims at becoming net-zero by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
Contacts for media:
Press Office Manager
Tel: +39 339 5897483